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Long-term outcomes in renal transplantation
Th e aim of oﬀ ering renal transplantation to patients with 
end-stage renal failure is to achieve a longer and better 
quality of life than can be achieved with dialysis therapy. 
For most patients this is being achieved, but the long-
term results come nowhere near what could be expected 
for the normal age-matched population. Th e Australia 
and New Zealand Dialysis and Transplant Registry 
(ANZDATA) shows that for patients transplanted with a 
primary deceased donor graft from 1995 to 2000 in 
Australia and New Zealand, 72% were alive 10 years after 
transplantation [1]. Of these, 20% had returned to dialysis 
therapy. Only 59% of these patients were thus alive with a 
functioning graft after 10 years.
Th e death rate after the ﬁ rst year for this cohort of 
patients is 2.5% per year. Deaths in the ﬁ rst few years 
relate to infection, with an increasing proportion due to 
malignancy and cardiovascular disease in later years. In 
2010 in Australia, 32% of deaths in transplant patients 
were due to malignancy, compared with 23% from 
cardiac or vascular disease and 22% from infection [1].
Whereas improvements in immunosuppression and 
surgical and medical advances have resulted in short-
term gains, the long-term outcomes have not improved. 
To illustrate this fact we have analysed ANZDATA for 
graft failure rates for transplants performed between 
1970 and 2009. Over those decades the graft failure rates 
have fallen substantially for the ﬁ rst year and to a lesser 
degree for the time periods of 1 to 4.9  years and 5 to 
9.9  years. For those grafts surviving 10  years, however, 
the subsequent annual failure rate has increased over 
time (Figure 1).
Role of immunosuppression in long-term 
outcomes
Th e role of chronic immunosuppression in adverse 
patient outcomes has long been recognised. Th e contri-
bution to mortality from infection is well known. In 
addition, the worsening of metabolic abnormalities such 
as diabetes and hyperlipidaemia and elevations in blood 
pressure contribute to cardiovascular risk. Immuno sup-
pres sion in combination with other onco genic stimuli 
such as viruses and ultraviolet radia tion causes signiﬁ cant 
increases in the risk of develop ment of certain cancers 
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such as Kaposi sarcoma, lym phoma and nonmelanotic 
skin cancers.
Diﬀ erent immunosuppressive drugs exhibit diﬀ erent 
proﬁ les of toxicity and may inﬂ uence in diﬀ erent ways 
the adverse outcomes seen in the long term. Much 
attention has been directed to the contribution of chronic 
nephrotoxicity of calcineurin inhibitors (CNIs) to long-
term graft failure. A study of protocol biopsies of renal 
allografts from 3 months to 10 years after transplantation 
by Nankivell and colleagues described the development 
of chronic allograft nephropathy (CAN) over time [2]. 
When changes of CAN – in particular, interstitial ﬁ brosis 
and tubular atrophy  – developed in the ﬁ rst year after 
transplantation, these were attributed to early events 
such as rejection and acute tubular necrosis. Lesions 
such as arteriolar hyalinosis and glomerulosclerosis 
developed later and were said to indicate damage from 
cyclosporine exposure.
Recently, doubt has been cast on the relative contri-
bution of CNI nephrotoxicity to long-term graft failure 
relative to other causes of graft damage such as T-cell-
mediated and antibody-mediated rejection, poly oma 
virus infection and recurrent glomerulo nephritis. In a 
North American study of biopsies of failing grafts, the 
dominant histological lesion seen at 5 years was chronic 
antibody-mediated rejection [3]. However, most of the 
biopsies were performed in response to deteriorating 
renal function or other clinical events at a median time of 
17  months after transplantation. Th is study therefore 
diﬀ ers from the study by Nankivell and colleagues, where 
the biopsies were performed at protocol-derived time 
points to 10 years.
Th ere are very few studies where the hard endpoints of 
graft loss or patient death give an indication of the 
adverse eﬀ ects of long-term CNI therapy. One of these 
studies is the Australian Multicentre Cyclosporine Renal 
Transplant Study, which has recently published results 
after 20  years of follow up [4]. Patients randomised to 
ongoing cyclosporine A (CsA) had an inferior outcome 
compared with patients who received CsA for 3 months 
before converting to azathioprine and corticosteroid. 
Th is study therefore supports that CNI exposure contri-
butes to deteriorating renal function and graft loss in the 
very long term after renal transplantation. Moreover, the 
study demonstrates that the eﬀ ect of CNI nephrotoxicity 
may not be clinically evident until the second decade 
after transplantation.
Much has also been made recently of the nonspeciﬁ c 
nature of the histopathological lesions purported to 
indicate evidence of CNI nephrotoxicity [5]. Whereas 
Figure 1. Graft failure rates per person-year for all renal transplants in Australia and New Zealand, 1970 to 2009. Graphs show rates by time 
after transplantation for era from 1970 divided into 5-year blocks [1]. ANZDATA, Australia and New Zealand Dialysis and Transplant Registry; NZ, New 
Zealand.
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many investigators concede that the lesions of arteriolar 
hyalinosis occur with chronic CNI toxicity, they are 
present in many other renal pathological conditions and 
may also be present at the time of transplantation as a 
result of donor-related disease. A recent study from 
France has demonstrated that the lesions described by 
Nankivell and colleagues as being characteristic of CAN 
and chronic CNI toxicity are seen in patients who have 
not been exposed to a CNI [6]. However, when com-
paring biopsies from patients who were receiving CNIs 
and those on sirolimus (SRL), the lesions of CNI 
arteriolopathy were more common in those patients 
receiving CNI therapy.
Rationale for mammalian target of rapamycin-
inhibitor use in renal transplantation
Mammalian target of rapamycin (mTOR) inhibitors have 
been shown to be eﬀ ective immunosuppressant agents in 
renal transplantation either in combination with a CNI 
or not. Th e main rationale for using these agents in a 
CNI-free regimen is to avoid the adverse events 
associated with CNI use, in particular chronic nephro-
toxicity. Th ere is, however, accumulating evidence that 
the avoidance of CNIs and the use of mTOR inhibitors 
also confer beneﬁ ts with respect to the development of 
malignancy and also some post-transplant infections.
Eff ect of mTOR inhibitors on post-transplant renal 
function
Th e ﬁ rst study to demonstrate the beneﬁ cial eﬀ ect of 
long-term CNI-free mTOR-inhibitor-based therapy in 
renal transplantation was the Rapamune Maintenance 
Regimen (RMR) study [7]. Patients were randomised at 
3 months to either continue a regimen of SRL, CsA and 
steroids, or to have CsA withdrawn with an increase in 
the concentration of the targeted dose of SRL. Although 
525 patients entered this study, 95 were not randomised 
because of signiﬁ cant rejection in the ﬁ rst 3  months or 
because of poor transplant function. Th e randomised 
patients were therefore a group selected for favourable 
outcomes. Nevertheless, in spite of having numerically 
greater numbers of rejections in the 3  months after 
randomisation, at 4 years the patients in whom CsA was 
withdrawn had superior renal function and graft survival 
compared with those who continued the combination of 
CsA and SRL. In addition, protocol biopsies performed at 
36  months showed less CAN in the CsA withdrawal 
group [8]. One valid criticism of this study is that the 
control arm of CsA and SRL is more nephrotoxic and 
would therefore provide an unfair comparator for both 
renal function and structure.
From in vitro experimental studies it has long been 
recognised that the combination of a CNI and an mTOR 
inhibitor provide immunological synergy. However, the 
main limitation of this combination in clinical practice is 
the enhanced nephro toxicity of the CNI. Randomised 
trials using everolimus with a reduced dose of CsA have 
nevertheless demon strated that eﬃ  cacy is maintained 
without any detriment to renal function, at least at the 
relatively early time point of 24 months [9]. Th is approach 
has allowed a 60% reduc tion in exposure to the CNI over 
a 12-month timeframe. Th e longer term eﬀ ect of this 
approach on renal function is not known and awaits 
further observation.
Other studies have used mTOR inhibitors as de novo 
therapy without concomitant CNI. Th e ORION study 
was a three-arm randomised controlled trial in which 
patients who received SRL, mycophenolate mofetil 
(MMF), steroid and basiliximab had a higher rate of acute 
rejection at 6 months compared with patients receiving a 
similar regimen but with tacrolimus rather than SRL [10]. 
In the Symphony study, patients were randomised to one 
of four treatment groups: MMF with standard-dose CsA 
and corticosteroids; MMF with low-dose CsA, daclizu-
mab and corticosteroids; MMF with low-dose tacrolimus, 
daclizumab and corticosteroids; or MMF with low-dose 
SRL, daclizumab and corticosteroids [11]. Th is study 
found that the regimen containing low-dose tacrolimus 
resulted in improved renal function, graft survival, and 
acute rejection rates compared with SRL/MMF and the 
other regimens, and that this was sustained over 3 years 
of follow up [12]. Even though the blood concentrations 
of SRL in these studies may have been lower than 
optimal, SRL/MMF would appear to be a less potent 
immuno suppressive combination than CNI/MMF, espe-
cially in the ﬁ rst few months after transplant when 
rejection is more likely to occur. A 2011 meta-analysis 
assessing outcomes associated with reducing CNI 
exposure from the time of transplantation found that 
there was no diﬀ erence in acute rejection rates with 
mTOR inhibitors and MMF in combination compared 
with CNI-based regimens (16  studies, n  =  2,688) [13]. 
Use of an mTOR-inhibitor/MMF combination imme di-
ately following transplant was associated with improved 
graft function but was also associated with increased 
graft failure, suggesting that the beneﬁ t of improved renal 
function is oﬀ set by increased graft loss [13].
Th e fact that long-term SRL without CNI showed 
excellent outcomes in terms of renal function at 5 years 
in the RMR study has prompted investigators to convert 
patients from a CNI to an mTOR inhibitor at varying 
times after transplantation with the aim of improving 
graft function. Th e CONVERT study examined late 
conversion, approximately 3  years after transplantation, 
from a CNI to SRL [14]. Two years after conversion, renal 
function improved (slightly but not signiﬁ cantly) in 
patients with good transplant function (glomerular 
ﬁ ltration rate (GFR) >40  ml/minute). Inferior outcomes 
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were seen in those with poorer function or signiﬁ cant 
proteinuria [14].
More recent studies have been published where con-
version has occurred earlier, and in general these 
approaches have been associated with greater beneﬁ t to 
renal function. Th e CONCEPT study is a randomised 
controlled trial from France demonstrating that 
conversion at 3 months from CsA to SRL in a regimen of 
CsA, mycophenolate, steroids and daclizumab leads to a 
clinically signiﬁ cant improvement in renal function 
without any detriment to graft or patient survival at 
12  months [15]. Th ere was an increase in the rejection 
rate in the conversion arm but this only occurred after 
steroids were withdrawn by protocol at 8  months [15]. 
Recently, the improvement in renal function has been 
demonstrated to be main tained to 5  years, with an 
approximately 10  ml/minute greater estimated GFR in 
the conversion group [16]. Similarly, the Spare-Th e-
Nephron study from the USA randomised patients on a 
CNI/mycophenolate/steroid regimen to conversion to a 
SRL/mycophenolate/steroid regimen 1 to 6 months after 
transplantation [17]. At 1 year, the measured GFR in the 
converted group had signiﬁ cantly improved by 24% 
compared with 5% in the control. Th e diﬀ erence between 
groups was maintained at 2  years. Similar results have 
been obtained when a CNI is converted to everolimus. 
Th e ZEUS study randomised patients to conversion at 
4.5 months from CsA to everolimus in combination with 
mycophenolate, steroids and induction with basiliximab 
[18]. At 1 year, the rejection rates were the same although 
there were numerically more episodes in the everolimus 
patients in the few months after conversion. Th ere was, 
however, approximately a 10  ml/minute higher GFR in 
the patients who converted to everolimus.
A meta-analysis of 22  randomised controlled trials 
assessed outcomes following conversion from CNIs to 
mTOR inhibitors for maintenance immunosuppression 
[19]. Th e analysis found that, compared with CNI-based 
regimens, mTOR-inhibitor-based regimens were asso-
ciated with improved renal function (estimated GFR) at 
12 months and this was sustained 5 years post transplant. 
When results at 12 months were stratiﬁ ed by time to con-
ver sion, early conversion (<12  months post trans plant) 
was found to result in improved graft function compared 
with later conversion. Th e estimated GFR (expressed as 
weighted mean diﬀ erence) was 5.07 ml/minute for early 
conversion, and was 2.85 ml/minute for later conversion. 
mTOR inhibitors were associated with a higher rate of 
rejection in the ﬁ rst 12 months, but there was no diﬀ er-
ence in rejection after 12 months. mTOR inhibitors were 
also associated with a lower risk of graft loss between 2 and 
5 years post conversion. Th e risk of adverse events, such as 
oedema, proteinuria and hyperlipidaemia, was higher for 
mTOR inhibitors, but infection rates were similar.
Th ere are two notable observations from these studies. 
Th e ﬁ rst is that rejection episodes occur after conversion 
in about 5 to 10% of patients. From the CONCEPT study, 
it would appear that there is a greater chance of rejection 
if steroids are withdrawn from an mTOR-inhibitor/MMF 
combination. Th ese rejection episodes are usually mild 
and easily reversible. A number of investigators have 
observed that it is critical to maintain adequate blood 
concentrations of mTOR inhibitors to reduce the rate of 
rejection. Th e second observation is that the tolerability 
of the mTOR inhibitor is such that up to 25% of patients 
return to the CNI-based combination. Th e usual reasons 
for poor tolerability are mouth ulcers, oedema, and 
dyslipidaemia.
Th e above studies suggest that renal graft function is 
better if conversion from a CNI to an mTOR inhibitor is 
performed between 1 and 6 months post transplant; and 
for patients who tolerate the mTOR inhibitor, this 
improvement is maintained for at least 2  years and 
possibly 5 years after conversion.
Eff ect of mTOR inhibitors on the development of 
post-transplant malignancy
Th ere are ﬁ rm theoretical and experimental reasons why 
mTOR inhibitors might protect against the development 
of malignancy. Th ere is now clinical evidence that 
patients treated with SRL have a lower rate of post-
transplant malignancy compared with those receiving 
CNI-based regimens [20]. In addition, mTOR inhibitors 
have shown further anti-cancer properties with promis-
ing results in the treatment of nontransplant patients 
with B-cell lymphomas and have been trialled in the 
treatment of relapsed mantle cell lymphoma [21].
Initially, registry analysis from the USA showed a lower 
incidence of both skin and solid organ malignancy in 
patients taking mTOR inhibitors (alone or in combination 
with CNIs) compared with patients on a CNI-based 
regimen [22]. Although they were not designed to evalu-
ate cancer outcomes, the RMR study [23], the CONVERT 
study [24] and the CONCEPT study [16] all showed a 
reduced rate of malignancy development after conversion 
from a CNI to an mTOR inhibitor. Th is reduction was 
true for both skin and solid organ malignancies. In the 
RMR study, patients who received SRL-based CNI-free 
immunosuppression experienced a signiﬁ cantly reduced 
risk of both skin cancer and nonskin cancer at 5  years 
after transplantation compared with those who received 
SRL/CNI combi nation therapy [23]. In the CONVERT 
study, the rate of cancer development was approximately 
one-third in those patients converted to SRL at 2  years 
after con version [24].
Th e only randomised controlled trial reported to date 
that has assessed cancer development after conversion 
from a CNI to an mTOR inhibitor has been the 407 skin 
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cancer study [25]. Performed predominantly in Australia, 
where the rate of post-transplant nonmelanotic skin 
cancer is high, 86 renal transplant patients were 
randomised to convert to SRL or to continue CNIs. Th e 
average time after transplant was almost 10  years, and 
tolerability of SRL was poor such that almost one-half of 
the converted patients did not maintain treatment with 
SRL. Follow up was for at least 1  year after conversion. 
Nevertheless, on analysis of the intention-to-treat popu-
lation, the rate of nonmelanoma skin cancer development 
was 2.48 per patient-year in the group continuing CNIs 
compared with 1.31 in the group converted to SRL 
(P = 0.022).
Two trials have focused on secondary skin cancer 
prevention and have found conﬂ icting results. In the 
RESCUE study [26] and the TUMORAPA study [27], 
patients with at least one biopsy-conﬁ rmed squamous 
cell carcinoma were randomly assigned to convert to SRL 
or to continue their original regimen. In the RESCUE 
study, results did not show a beneﬁ t of conversion to SRL 
in terms of squamous cell carcinoma-free survival at 
2-year follow up [26]. In the TUMORAPA study, how-
ever, SRL demonstrated a signiﬁ cant anti-tumoural eﬀ ect 
at 2  years with a decreased risk of new squamous cell 
carcinoma and longer time to development of new 
lesions [27].
Overall, the evidence thus suggests that conversion to 
SRL after transplantation is associated with a lower rate 
of malignancy development compared with continuation 
of CNIs, and that the diﬀ erence is evident as early as 
1 year after conversion, at least for patients at risk of skin 
cancer development.
A lower rate of viral disease after transplantation 
with mTOR-inhibitor therapy
Th ere is now convincing evidence that immuno-
suppressive regimens, including mTOR inhibitors, are 
associated with less cytomegalovirus infection and 
disease (reviewed in [28]). Rates of cytomegalovirus are 
lower with both SRL [15] and everolimus [9], in recipients 
of kidney [9,15] and heart [29] grafts, whether the mTOR 
inhibitor is used with or without a CNI, and whether or 
not anti-viral prophylaxis is used [30].
Rates of BK virus infection have also been shown to be 
lower with mTOR-inhibitor-based regimens, with data 
showing a lower rate of BK virus-related events in 
patients receiving everolimus or SRL [31].
Eff ect of mTOR inhibitors on cardiovascular disease
Along with cancer, cardiovascular disease is one of the 
main causes of death with a functioning graft [1]. 
Immunosuppressants have diﬀ ering eﬀ ects on cardio-
vascular risk factors, such as hypertension, left ventri-
cular hyperplasia, and dyslipidaemia, and selection of 
immunosuppression may be used to help control these 
risk factors. Conversion from CNI-based to mTOR-
inhibitor-based immunosuppression has been shown to 
improve blood pressure and may achieve regression of 
left ventricular hyperplasia. In the RMR study, it was 
found that conversion to SRL resulted in signiﬁ cantly 
better mean arterial blood pressure at most time points 
from 6 to 48  months. Patients converted to SRL also 
received fewer anti-hypertensive drugs [7]. However, the 
group converted to SRL also had signiﬁ cantly higher 
levels of high-density lipoprotein cholesterol. Dyslipidae-
mia has been found to be more prevalent in patients 
converted to mTOR-inhibitor-based regimens, with 
increased levels of cholesterol and triglycerides, and an 
increased use of lipid-lowering agents [32]. Experimental 
and clinical studies have shown that SRL may be eﬀ ective 
in achieving regression of left ventricular hyperplasia 
[33]; more trials are needed in this area.
Conclusion
Th e beneﬁ t of a long-term CNI-free mTOR-inhibitor-
based regimen after renal transplant is the promise of 
reduced development of chronic damage to the graft 
mediated by CNI, and a lower incidence of post-trans-
plant malignancy. CNI-free mTOR-inhibitor-based 
regimens are less eﬃ  cacious with respect to rejection 
prophylaxis and their use in the de novo transplant is not 
recommended. Conversely, when conversion from a CNI 
to an mTOR inhibitor is performed late, the patient has 
GFR <40  ml/minute, or the patient has pre-existing 
proteinuria, as in the CONVERT study, then beneﬁ t is 
blunted. Th e studies that have shown the greatest beneﬁ t 
in terms of renal allograft function are those where 
conversion is attempted between 1 and 6  months after 
transplantation. When patients have been able to tolerate 
a switch from a CNI to an mTOR inhibitor in this time 
period, the beneﬁ ts in the medium term are better 
allograft function, a lower incidence of cancer, and 
possibly a lower rate of viral infection. Th e long-term 
impact (beyond 10  years) of this strategy requires well-
designed trials with late follow up, which would only be 
possible using registries such as ANZDATA.
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